Akebia Therapeutics (AKBA) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results
November 12, 2019 7:57 AM ESTFunding expected to extend Companys cash runway into 2021, well past its expected topline data readouts for global Phase 3 studies for vadadustat; MTPCs positive Phase 3 data show vadadustats effect on hemoglobin was sustained through to 52 weeks; Auryxia ® (ferric citrate) revenue increases to $30.0 million for Q3FY19, up 13% from Q3FY18; and, Company hosts call to discuss financial results and recent business highlights
CAMBRIDGE, Mass.--(BUSINESS... More
